Introduction of quarterly dividends from 2026...plan to pay 800 won per year
Huons Global posted consolidated sales of 847.5 billion won, operating profit of 90.6 billion won, and net profit of 80.7 billion won for 2025. Compared with the previous year, sales increased by 4.2%, operating profit decreased by 6.6%, and net profit rose by 20.2%.
In the fourth quarter, the company reported sales of 224.5 billion won, operating profit of 19.4 billion won, and net profit of 14.3 billion won. Sales grew 10.9% year-on-year, surpassing 220 billion won in quarterly revenue for the first time. Operating profit fell 26.0%, while net profit increased 19.8%.
The company decided on a year-end cash dividend of 200 won per share. The record date for the dividend is April 3. The total dividend for the 2025 fiscal year is 880 won per share, up 68% from the previous year. The total dividend payout amounts to 10.7 billion won.
For 2026, the company plans to pay 200 won per share each quarter, or 800 won per share for the full year. It also announced a mid- to long-term dividend policy to raise the per-share dividend each year by a range of 5% to 30% through 2028. The dividend funds will come from a reduction of capital surplus in the form of a capital reduction dividend.
The results of major subsidiaries were also made public. Huons Meditech recorded standalone sales of 170.1 billion won, operating profit of 42.3 billion won, and net profit of 50.0 billion won. Sales increased by 5%, operating profit decreased by 2%, and net profit rose by 27%. New products and the expansion of the cosmetics business drove sales growth.
HuM&C posted sales of 52.3 billion won, operating profit of 2.5 billion won, and net profit of 1.4 billion won. Sales increased by 11%, but due to initial stabilization costs at its Vietnam plant, operating profit and net profit declined by 50% and 58%, respectively.
Huons Biopharma saw an overall decline in results, but exports of its botulinum toxin product Hutox reached 16.4 billion won, up 16.7% from the previous year. The company recently obtained product approval in China and is preparing to enter the Chinese market.
The company explained that although it achieved record-high sales thanks to export expansion and the growth of key affiliates, its operating margin edged down due to a higher cost ratio following production capacity expansion. This year, it plans to secure growth engines by simultaneously improving profitability and investing in research and development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
